{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:10:01Z","timestamp":1792919401610,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100008792","name":"novartis pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"novo nordisk pharma gmbh"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12020-021-02954-0","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T13:04:02Z","timestamp":1645016642000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature"],"prefix":"10.1007","volume":"76","author":[{"given":"Piotr","family":"Sumislawski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rotermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lautenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika K.","family":"Wefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Soltwedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Flitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-8523","authenticated-orcid":false,"given":"Wolfgang","family":"Saeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"2954_CR1","doi-asserted-by":"publisher","unstructured":"P.J. Pernicone, B.W. Scheithauer, T.J. Sebo et al., Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer. (1997). https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19970215)79:43.0.CO;2-3","DOI":"10.1002\/(SICI)1097-0142(19970215)79:43.0.CO;2-3"},{"key":"2954_CR2","doi-asserted-by":"publisher","unstructured":"F. Yoo, E.C. Kuan, A.P. Heaney, M. Bergsneider, M.B. Wang, Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary. (2018). https:\/\/doi.org\/10.1007\/s11102-018-0872-8.","DOI":"10.1007\/s11102-018-0872-8"},{"key":"2954_CR3","doi-asserted-by":"publisher","unstructured":"J.M. van der Zwan, S. Mallone, B. van Dijk et al., Carcinoma of endocrine organs: Results of the RARECARE project. Eur. J. Cancer. (2012). https:\/\/doi.org\/10.1016\/j.ejca.2012.01.029","DOI":"10.1016\/j.ejca.2012.01.029"},{"key":"2954_CR4","doi-asserted-by":"publisher","unstructured":"T.M. Hansen, S. Batra, M. Lim et al., Invasive adenoma and pituitary carcinoma: A SEER database analysis. Neurosurg. Rev. (2014). https:\/\/doi.org\/10.1007\/s10143-014-0525-y","DOI":"10.1007\/s10143-014-0525-y"},{"key":"2954_CR5","doi-asserted-by":"publisher","unstructured":"P.N. Els\u00e4sser Imboden, F.X. Borruat, N. de Tribolet, K. Meagher-Villemure, A. Pica, F. Gomez, Non-functioning pituitary carcinoma. Pituitary. (2004). https:\/\/doi.org\/10.1007\/s11102-005-3411-3","DOI":"10.1007\/s11102-005-3411-3"},{"key":"2954_CR6","unstructured":"R.V. Lloyd, R.Y. Osamura, G.R.J. Kl\u00f6ppel, WHO Classification of Tumours of Endocrine Organs, 4th edn. (WHO-OMS, Lyon; 2017)."},{"key":"2954_CR7","doi-asserted-by":"publisher","unstructured":"G.A. Kaltsas, A.B. Grossman, Malignant pituitary tumours. Pituitary. (1998). https:\/\/doi.org\/10.1023\/A:1009975009924","DOI":"10.1023\/A:1009975009924"},{"issue":"4","key":"2954_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/CLINEM\/DGAA749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"O. Casar-Borota, H.B. Boldt, B.E. Engstr\u00f6m, et al., Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J. Clin. Endocrinol. Metabolism 106(4), 1183 (2021). https:\/\/doi.org\/10.1210\/CLINEM\/DGAA749","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"2","key":"2954_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","volume":"156","author":"DK L\u00fcdecke","year":"2007","unstructured":"D.K. L\u00fcdecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, W. Saeger, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156(2), 203\u2013216 (2007). https:\/\/doi.org\/10.1530\/eje.1.02326","journal-title":"Eur. J. Endocrinol."},{"key":"2954_CR10","doi-asserted-by":"publisher","unstructured":"Heaney A.P. Pituitary carcinoma: Difficult diagnosis and treatment. J. Clin. Endocrinol. Metabolism. 96(12), 3649\u22123660 (2011). https:\/\/doi.org\/10.1210\/jc.2011-2031","DOI":"10.1210\/jc.2011-2031"},{"issue":"9","key":"2954_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/PAS.0000000000000908","volume":"41","author":"O Casar-Borota","year":"2017","unstructured":"O. Casar-Borota, J. Botling, D. Granberg, et al., Serotonin, ATRX, and DAXX expression in pituitary adenomas: markers in the differential diagnosis of neuroendocrine tumors of the sellar region. Am. J. Surg. Pathol. 41(9), 1238\u20131246 (2017). https:\/\/doi.org\/10.1097\/PAS.0000000000000908","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"2954_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/S12022-017-9474-7","volume":"28","author":"N Tufton","year":"2017","unstructured":"N. Tufton, F. Roncaroli, I. Hadjidemetriou, et al., Pituitary carcinoma in a patient with an SDHB mutation. Endocrine Pathol. 28(4), 320 (2017). https:\/\/doi.org\/10.1007\/S12022-017-9474-7","journal-title":"Endocrine Pathol."},{"key":"2954_CR13","doi-asserted-by":"publisher","unstructured":"Y. Tanizaki, L. Jin, B.W. Scheithauer, K. Kovacs, F. Roncaroli, R. v. Lloyd, P53 gene mutations in pituitary carcinomas. Endocrine Pathol. (2007). https:\/\/doi.org\/10.1007\/s12022-007-9006-y","DOI":"10.1007\/s12022-007-9006-y"},{"issue":"4","key":"2954_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1210\/jcem.78.4.8157709","volume":"78","author":"L Pei","year":"1994","unstructured":"L. Pei, S. Melmed, B. Scheithauer, K. Kovacs, D. Prager, H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metabol. 78(4), 842\u2013846 (1994). https:\/\/doi.org\/10.1210\/jcem.78.4.8157709","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"11","key":"2954_CR15","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1210\/jc.2017-01401","volume":"102","author":"D Bengtsson","year":"2017","unstructured":"D. Bengtsson, P. Joost, C. Aravidis, et al., Corticotroph pituitary carcinoma in a patient with Lynch Syndrome (LS) and pituitary tumors in a nationwide LS cohort. J. Clin. Endocrinol. Metabolism 102(11), 3928\u20133932 (2017). https:\/\/doi.org\/10.1210\/jc.2017-01401","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"2954_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/FONC.2018.00510","volume":"8","author":"F Guo","year":"2018","unstructured":"F. Guo, G. Wang, F. Wang, D. Xu, X. Liu, Identification of novel genes involved in the pathogenesis of an ACTH-secreting pituitary carcinoma: A case report and literature review. Front. Oncol. 8, 510 (2018). https:\/\/doi.org\/10.3389\/FONC.2018.00510","journal-title":"Front. Oncol."},{"key":"2954_CR17","doi-asserted-by":"publisher","unstructured":"B.T. Ragel, W.T. Couldwell, Pituitary carcinoma: a review of the literature. Neurosurg. Focus. (2004). https:\/\/doi.org\/10.3171\/foc.2004.16.4.8","DOI":"10.3171\/foc.2004.16.4.8"},{"issue":"3","key":"2954_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","volume":"23","author":"A Lacroix","year":"2020","unstructured":"A. Lacroix, F. Gu, J. Schopohl, et al., Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u2019s disease: results from a Phase 3 study. Pituitary 23(3), 203\u2013211 (2020). https:\/\/doi.org\/10.1007\/s11102-019-01021-2","journal-title":"Pituitary"},{"key":"2954_CR19","doi-asserted-by":"publisher","unstructured":"A. Heaney, Management of aggressive pituitary adenomas and pituitary carcinomas. J. Neuro-Oncol. (2014). https:\/\/doi.org\/10.1007\/s11060-014-1413-6","DOI":"10.1007\/s11060-014-1413-6"},{"key":"2954_CR20","doi-asserted-by":"publisher","unstructured":"P. Kamenick\u00fd, C. Droumaguet, S. Salenave et al., Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J. Clin. Endocrinol. Metabolism. (2011). https:\/\/doi.org\/10.1210\/jc.2011-0536","DOI":"10.1210\/jc.2011-0536"},{"key":"2954_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41379-020-0523-2","volume":"33","author":"CM Heaphy","year":"2020","unstructured":"C.M. Heaphy, Bi.L. Wenya, et al., Telomere length alterations and ATRX\/DAXX loss in pituitary adenomas. Modern Pathol. 33, 1475\u20131481 (2020). https:\/\/doi.org\/10.1038\/s41379-020-0523-2","journal-title":"Modern Pathol."},{"issue":"13","key":"2954_CR22","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1242\/jcs.099663","volume":"125","author":"H Solomon","year":"2012","unstructured":"H. Solomon, Y. Buganim, I. Kogan-Sakin, et al., Various p53 mutant proteins differently regulate the ras circuit to induce a cancer-related gene signature. J. Cell Sci. 125(13), 3144\u20133152 (2012). https:\/\/doi.org\/10.1242\/jcs.099663","journal-title":"J. Cell Sci."},{"issue":"6","key":"2954_CR23","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1158\/0008-5472.CAN-09-2661","volume":"70","author":"Y Buganim","year":"2010","unstructured":"Y. Buganim, H. Solomon, Y. Rais, et al., p53 regulates the ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 70(6), 2274\u20132284 (2010). https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2661","journal-title":"Cancer Res."},{"issue":"6","key":"2954_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/sj.cdd.4401904","volume":"13","author":"KL Harms","year":"2006","unstructured":"K.L. Harms, X. Chen, The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differentiation 13(6), 890\u2013897 (2006). https:\/\/doi.org\/10.1038\/sj.cdd.4401904","journal-title":"Cell Death Differentiation"},{"issue":"5","key":"2954_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.biocel.2004.11.014","volume":"37","author":"H Scrable","year":"2005","unstructured":"H. Scrable, T. Sasaki, B. Maier, \u0394Np53 or p44: Priming the p53 pump. Int. J. Biochem. Cell Biol. 37(5), 913\u2013919 (2005). https:\/\/doi.org\/10.1016\/j.biocel.2004.11.014","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"51","key":"2954_CR26","doi-asserted-by":"publisher","first-page":"39927","DOI":"10.1074\/jbc.M005676200","volume":"275","author":"J Zhu","year":"2000","unstructured":"J. Zhu, S. Zhang, J. Jiang, X. Chen, Definition of the p53 functional domains necessary for inducing apoptosis. J. Biol. Chem. 275(51), 39927\u201339934 (2000). https:\/\/doi.org\/10.1074\/jbc.M005676200","journal-title":"J. Biol. Chem."},{"key":"2954_CR27","doi-asserted-by":"publisher","unstructured":"F. D\u2019Angelo, M. Ceccarelli, Tala et al., The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. (2019). https:\/\/doi.org\/10.1038\/s41591-018-0263-8","DOI":"10.1038\/s41591-018-0263-8"},{"key":"2954_CR28","doi-asserted-by":"publisher","unstructured":"S. Ben-Salem, A.M. Al-Shamsi, B.R. Ali, L. Al-Gazali, The mutational spectrum of the NF1 gene in neurofibromatosis type I patients from UAE. Child\u2019s Nervous Syst. (2014). https:\/\/doi.org\/10.1007\/s00381-013-2352-9","DOI":"10.1007\/s00381-013-2352-9"},{"issue":"5","key":"2954_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"N. Ratner, S.J. Miller, A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15(5), 290\u2013301 (2015). https:\/\/doi.org\/10.1038\/nrc3911","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"2954_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers11111765","volume":"11","author":"L Salvatore","year":"2019","unstructured":"L. Salvatore, M.A. Calegari, F. Loupakis, et al., PTEN in colorectal cancer: Shedding light on its role as predictor and target. Cancers 11(11), 1765 (2019). https:\/\/doi.org\/10.3390\/cancers11111765","journal-title":"Cancers"},{"issue":"10","key":"2954_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02915-8","volume":"37","author":"A Lalatsa","year":"2020","unstructured":"A. Lalatsa, Y. Sun, J.I. Gamboa, S. Knafo, Preformulation studies of a stable PTEN-PDZ lipopeptide able to cross an in vitro blood-brain-barrier model as a potential therapy for Alzheimer\u2019s disease. Pharm. Res. 37(10), 1\u201313 (2020). https:\/\/doi.org\/10.1007\/s11095-020-02915-8","journal-title":"Pharm. Res."},{"issue":"3","key":"2954_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1947601911408079","volume":"2","author":"E Castellano","year":"2011","unstructured":"E. Castellano, J. Downward, Ras interaction with PI3K: More than just another effector pathway. Genes and Cancer. 2(3), 261\u2013274 (2011). https:\/\/doi.org\/10.1177\/1947601911408079","journal-title":"Genes and Cancer."},{"key":"2954_CR33","doi-asserted-by":"publisher","unstructured":"F. Luongo, F. Colonna, F. Calap\u00e0, S. Vitale, M.E. Fiori, R. De Maria, Pten tumor-suppressor: The dam of stemness in cancer. Cancers. (2019). https:\/\/doi.org\/10.3390\/cancers11081076.","DOI":"10.3390\/cancers11081076"},{"issue":"6","key":"2954_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jnci\/djs648","volume":"105","author":"G Xue","year":"2013","unstructured":"G. Xue, B.A. Hemmings, PKB\/akt-dependent regulation of cell motility. J. Natl Cancer Institute 105(6), 393\u2013404 (2013). https:\/\/doi.org\/10.1093\/jnci\/djs648","journal-title":"J. Natl Cancer Institute"},{"key":"2954_CR35","doi-asserted-by":"publisher","unstructured":"Bazzichetto C., Conciatori F., Pallocca M., et al., Pten as a prognostic\/predictive biomarker in cancer: An unfulfilled promise? Cancers. (2019). https:\/\/doi.org\/10.3390\/cancers11040435","DOI":"10.3390\/cancers11040435"},{"issue":"1","key":"2954_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1530\/EJE-17-0634","volume":"178","author":"LG P\u00e9rez-Rivas","year":"2018","unstructured":"L.G. P\u00e9rez-Rivas, M. Theodoropoulou, T.H. Puar, et al., Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson\u2019s tumor. Eur. J. Endocrinol. 178(1), 57\u201363 (2018). https:\/\/doi.org\/10.1530\/EJE-17-0634","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"2954_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/NEUONC\/NOZ109","volume":"21","author":"S Sbiera","year":"2019","unstructured":"S. Sbiera, L.G. Perez-Rivas, L. Taranets, et al., Driver mutations in USP8 wild-type Cushing\u2019s disease. Neuro-Oncology 21(10), 1273 (2019). https:\/\/doi.org\/10.1093\/NEUONC\/NOZ109","journal-title":"Neuro-Oncology"},{"key":"2954_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/S40478-015-0229-8","volume":"3","author":"CP Miermeister","year":"2015","unstructured":"C.P. Miermeister, S. Petersenn, M. Buchfelder, et al., Histological criteria for atypical pituitary adenomas\u2014data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol. Commun. 3, 50 2015). https:\/\/doi.org\/10.1186\/S40478-015-0229-8","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"2954_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"R. Yaeger, R.B. Corcoran, Targeting alterations in the RAF\u2013MEK pathway. Cancer Discov. 9(3), 329\u2013341 (2019). https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1321","journal-title":"Cancer Discov."},{"issue":"1","key":"2954_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cells9010198","volume":"9","author":"U Degirmenci","year":"2020","unstructured":"U. Degirmenci, M. Wang, J. Hu, Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells 9(1), 198 (2020). https:\/\/doi.org\/10.3390\/cells9010198","journal-title":"Cells"},{"key":"2954_CR41","doi-asserted-by":"publisher","unstructured":"A.S. Alzahrani. PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside. Semin. Cancer Biol. (2019). https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.009","DOI":"10.1016\/j.semcancer.2019.07.009"},{"issue":"1","key":"2954_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00635-y","volume":"6","author":"C Yang","year":"2021","unstructured":"C. Yang, G. Lou, W.-L. Jin, The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies. Signal Transduct. Targeted Ther. 6(1), 1\u20132 (2021). https:\/\/doi.org\/10.1038\/s41392-021-00635-y","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7","key":"2954_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14728222.2018.1487953","volume":"22","author":"S Haase","year":"2018","unstructured":"S. Haase, M.B. Garcia-Fabiani, S. Carney, et al., Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin. Ther. Targets 22(7), 599 (2018). https:\/\/doi.org\/10.1080\/14728222.2018.1487953","journal-title":"Expert Opin. Ther. Targets"},{"key":"2954_CR44","doi-asserted-by":"publisher","unstructured":"C. Dai, S. Liang, B. Sun, J. Kang. The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front. Endocrinol. (2020). https:\/\/doi.org\/10.3389\/FENDO.2020.608422","DOI":"10.3389\/FENDO.2020.608422"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02954-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:25:50Z","timestamp":1649247950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02954-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02954-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors (Piotr Sumislawski, Roman Rotermund, Silke Klose, Anne Lautenbach, Annika K. Wefers, Celina Soltwedel, Behnam Mohammadi, Frank Jacobsen, Christian Mawrin, J\u00f6rg Flitsch, Wolfgang Saeger) declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (a separate ethic review and permission of a local committee was not necessary according to \u00a7 12 to the Hamburgisches Krankenhausgesetz, Hamburg, Germany). We currently state that written informed consent including medical photographs was obtained from the participant for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}